Browse the evidence

Hyperglycemia and insulin resistance drive Coronary Microvascular Dysfunction (CMD) through oxidative stress, inflammation, and reduced nitric oxide (NO) bioavailability, leading to endothelial dysfunction.

Controlling blood sugar and insulin resistance is critical not just for nerves and kidneys, but for heart health. High glucose and insulin resistance directly damage the heart's small blood vessels by creating oxidative stress and reducing the body's ability to dilate blood vessels (NO bioavailability).

GLP-1 receptor agonists are associated with an increased risk of gastrointestinal side effects (nausea, vomiting, diarrhea) and rare serious adverse events (gallbladder disorders, pancreatitis), as well as emerging risks related to delayed gastric emptying affecting anesthesia and endoscopy.

Be aware that nausea, vomiting, and diarrhea are common when starting GLP-1 medications, but they often improve over time. Serious side effects like gallbladder issues or pancreatitis are rare but require medical attention. If you need surgery or a colonoscopy, inform your provider, as they may need to adjust your medication schedule to prevent complications like aspiration.

Current 'exercise mimetic' compounds fail to replicate the broad health benefits of exercise because they target only skeletal muscle pathways, ignoring critical cardiovascular, autonomic, and systemic adaptations.

Do not rely on 'exercise pills' or mimetics for comprehensive health. They currently only affect muscle metabolism and miss crucial cardiovascular and systemic benefits. The most effective strategy remains actual physical activity or, for cardiovascular risk management, evidence-based polypills if exercise is not possible, though even these do not fully replace exercise.

Exercise mimetics fail to replicate exercise's cardiovascular benefits because they do not address the hemodynamic stimuli (shear stress, pressure) that directly regulate arterial health and endothelial function.

Exercise benefits the heart and arteries through mechanical forces (blood flow, pressure) that pills cannot replicate. This is why exercise remains superior for cardiovascular health compared to any current pharmacological intervention.

Sustained lipid mobilization (fat loss) leads to the disassembly of caveolae through the degradation of cavin proteins (cavin-1, cavin-2, EHD2), reducing caveolae density.

When you lose fat, your fat cells physically change structure. This paper shows that as fat is burned, the 'caveolae' structures on the cell surface break down. This is a natural adaptation to smaller cell size.

GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.

GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.

Intensive lifestyle intervention (ILI) focused on weight loss does not significantly reduce all-cause mortality in older adults with type 2 diabetes and overweight/obesity compared to diabetes support and education (DSE) over a median of 16.7 years.

For older adults with type 2 diabetes, engaging in intensive lifestyle programs (diet and exercise) is recommended to improve quality of life, fitness, and metabolic health, but should not be undertaken with the expectation that it will significantly extend lifespan compared to standard diabetes education. The intervention is safe and does not increase mortality risk.

Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.

Your gut contains specialized cells that sense what you eat and send signals to your brain and pancreas to regulate hunger and blood sugar. This natural system can be targeted by medications to treat metabolic diseases.

Obesity is an independent proarrhythmic risk factor for both atrial and ventricular arrhythmias, mediated by structural remodeling (atrial/ventricular dilation, epicardial fat infiltration) and electrophysiological changes (prolonged QTc, P-wave dispersion).

Obesity directly increases the risk of heart rhythm problems (atrial and ventricular arrhythmias) through structural changes like heart enlargement and fat infiltration around the heart. This risk exists independently of other conditions like high blood pressure. Weight loss is a key intervention to reduce this risk.

Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.

Understand that after weight loss, your body biologically fights to regain weight through increased hunger and slower metabolism. This is not a failure of willpower but a physiological defense. Successful maintenance requires acknowledging this biological reality and often necessitates ongoing, lifelong behavioral or medical support to counter these natural drives.

Loss-of-function mutations in the central melanocortin system (specifically MC4R, POMC, or AgRP pathways) consistently increase fat preference and decrease carbohydrate preference in both rodents and humans.

For individuals with specific genetic variants affecting the melanocortin system, there is a biological predisposition toward higher fat preference and lower carbohydrate preference. Recognizing this can help in selecting dietary strategies that align with these preferences or manage them through environmental control.

The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.

Your brain uses signals from your gut (like GLP-1 and ghrelin) and fat cells (leptin) to decide how hungry you are and how much energy you burn. In obesity, this system is broken, defending a higher weight.

Body Mass Index (BMI) is an inadequate and potentially misleading metric for assessing individual cardiometabolic risk because it fails to account for regional fat distribution and ectopic lipid deposition, which are the true drivers of disease.

Stop using BMI as your primary health metric. Instead, focus on waist circumference and metabolic markers (blood pressure, lipids, glucose). If you have a high BMI but a small waist and good metabolic markers, your risk may be low. Conversely, if you have a normal BMI but a large waist, your risk may be high. Prioritize lifestyle habits (diet quality, physical activity) that reduce visceral fat rather than just total weight.

Obesity is fundamentally a disorder of energy balance where excess energy intake exceeds expenditure, driven by a feedback system derangement involving economic, hedonic, and behavioral overrides rather than simple thermodynamic inefficiency.

Understand that obesity is not just a simple math problem of calories in vs. calories out, but a complex regulatory failure influenced by your environment and biology. To manage weight, you must address the 'hedonic overrides' (taste, convenience, cost) that disrupt your natural energy balance feedback loops, rather than relying solely on willpower.

Obesity is a chronic disease driven by pathophysiologic dysregulation of energy balance (neural, hormonal, metabolic pathways), not merely a behavioral failure of discipline.

Stop blaming yourself for your weight. Your body's biology (hormones, brain signals) is actively fighting weight loss. This is a medical condition, not a moral failure. Effective treatment requires addressing the biology, not just 'trying harder'.

Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.

Stop blaming yourself for your weight. Obesity is a chronic disease driven by your body's physiology, not just your willpower. Seek medical treatment because your body is fighting you, and you need professional help to manage it.

SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.

If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.

Exposure to aerial environmental stressors, specifically fine particulate matter (PM2.5) and gaseous pollutants, causes cardiovascular disease and mortality through systemic inflammation, oxidative stress, and autonomic nervous system imbalance.

Monitor local air quality indices (AQI) and smog alerts. On days with high pollution, limit prolonged outdoor exertion, especially near traffic. Consider using air purifiers indoors and keeping windows closed during peak pollution times. This is a modifiable risk factor that acts independently of your diet and exercise habits.

Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.

Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.

Obesity is a chronic, highly heritable neurological disease driven by central nervous system regulation of satiety and reward, rather than solely a behavioral failure of willpower.

Obesity is a biological condition involving brain pathways that control hunger and reward, heavily influenced by genetics. This means it is not simply a failure of willpower. Effective management often requires addressing these biological drivers, potentially through medical therapies that target these specific pathways, rather than relying solely on lifestyle changes which may be insufficient for those with high genetic risk.

Nutritional supplementation alone does not improve mobility or physical function in older adults when compared to physical activity interventions.

Do not rely on supplements to keep you mobile. While a healthy diet is important, it does not replace the need for physical activity. Focus on exercise groups rather than buying supplements for mobility.

GLP-1 receptor agonists provide significant cardiovascular risk reduction in both diabetic and non-diabetic patients with established cardiovascular disease, a benefit that is significantly under-recognized by physicians, particularly for non-diabetic patients.

For patients with obesity and established cardiovascular disease, GLP-1 agonists offer significant cardiovascular risk reduction (20% reduction in MACE in non-diabetics). Prescribers should be aware of these benefits to ensure appropriate patient selection and counseling, regardless of diabetic status.

The gut pathobiont Bilophila wadsworthia acts as a glycine sink by metabolizing glycine via the glycine reductase pathway, thereby lowering circulating glycine levels and negatively impacting metabolic markers.

The presence of the gut bacteria Bilophila wadsworthia consumes glycine, reducing its beneficial effects. Vegan diets tend to reduce this bacteria, thereby increasing glycine. While probiotics targeting this specific bacteria are not yet standard, understanding this link highlights why microbiome composition matters for metabolic health.

Imaging-based body composition assessment (DXA, CT, or MRI) is required to demonstrate that weight loss from anti-obesity drugs is attributable to fat mass reduction rather than lean mass loss, as mandated by updated US FDA and Korean MFDS guidelines.

If you are taking anti-obesity medication, ask your provider about body composition analysis (DXA or CT) rather than relying solely on weight. This ensures your weight loss is coming from fat stores and not muscle tissue, which is critical for long-term metabolic health and is now a regulatory standard for drug approval.